October 21 results are due for Genomma Lab stock

Published on 10/16/2026 at 15:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue consensus was MXN 4.57 billion on October 6, 2026. Genomma Lab stock is EUR 0.67 on October 16, 2026, up 0.07 percent versus the BMV close.

Upcoming results and market data

Genomma Lab is scheduled to report third-quarter results on October 21, 2026.
A consensus dated October 6, 2026 put revenue at MXN 4.57 billion, 2.89 percent above the prior-year quarter.
Genomma Lab stock is EUR 0.67 at Lang & Schwarz on October 16, 2026 at 3:35 p.m. CEST, with the BMV listing up 0.07 percent.
The price-to-earnings ratio was 8.36 and market capitalization MXN 13.5 billion on October 15, 2026.

Genomma Lab, MX01LA010006, Illustration mit AI erstellt.

Genomma Lab is scheduled to report its third-quarter 2026 results on October 21, 2026, after the Mexican Stock Exchange closes, according to Yahoo Finance. The company has also scheduled an earnings call for October 22, 2026. The Lang & Schwarz quote was EUR 0.67 on October 16, 2026 at 3:35 p.m. CEST. The BMV listing was up 0.07 percent versus its October 14 close.

Revenue expectations point higher

finanzen.net reported on October 6, 2026 that one analyst expected third-quarter revenue of MXN 4.57 billion, up 2.89 percent from MXN 4.44 billion in the prior-year quarter. The same estimate put earnings per share at MXN 0.46, versus MXN 0.44 a year earlier.

That forecast gives the October 21 report a clear numerical benchmark. A revenue result above MXN 4.57 billion would exceed the cited estimate, while the earnings figure has a narrower comparison point at MXN 0.46.

Stock sits below its yearly high

Genomma Lab's BMV quote was MXN 13.79 on October 15, 2026, with a daily gain of 0.07 percent. The 52-week range was MXN 12.22 to MXN 19.48 on the same date. The share price stood 29.21 percent below the upper end of that range. Trading volume was 3,334,246 shares, compared with an average of 3,492,035 shares.

Valuation and upcoming dates

Genomma Lab had a market capitalization of MXN 13.5 billion and a price-to-earnings ratio of 8.36 as of October 15, 2026. Its dividend yield was 0.06 percent. The next scheduled company date is the third-quarter results release on October 21, 2026, followed by the conference call on October 22, 2026.

Comparison with peers

Genomma Lab (BMV, MXN): plus 0.07 percent, P/E 8.36, market capitalization MXN 13.5 billion.
Kimberly-Clark de Mexico (BMV, MXN): minus 0.07 percent, P/E 15.12, market capitalization MXN 119.6 billion.
Grupo Herdez (BMV, MXN): minus 0.56 percent, P/E 0.88, market capitalization MXN 17.8 billion.

What the October dates add

The two scheduled dates separate the financial release from management's discussion. For investors, the key numerical tests are the MXN 4.57 billion revenue estimate and the MXN 0.46 earnings-per-share estimate, both dated October 6, 2026.

Market position

Genomma Lab's valuation is lower than Kimberly-Clark de Mexico's price-to-earnings ratio but higher than Grupo Herdez's ratio on the cited market figures. The stock also remains materially below its MXN 19.48 52-week high.

The further course of trading is shown by the continuously updated real-time quote of Genomma Lab stock.